로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Integrin alpha V beta 6

Integrin alpha V beta 6

요약

Name:Integrin alpha-V/beta-6
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

IT6-M52W9-ELISA
Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag FreeMouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-M52W9) ELISA bioactivity

Immobilized Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-M52W9) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 0.3-10 ng/mL (QC tested).

IT6-M52W9-MALS-HPLC
Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. ) MALS images

The purity of Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-M52W9) is more than 90% and the molecular weight of this protein is around 189-231 kDa verified by SEC-MALS.

Bioactivity-ELISA
Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag FreeMouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-M52W9) ELISA bioactivity

Immobilized Mouse ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-M52W9) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 0.3-10 ng/mL (QC tested).

사용자 리뷰

Synonym Name

Integrin alpha V beta 6,ITGAV&ITGB6

Background

Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
BG-00011 hu3G9; STX-100; BG-00011 Biogen Inc Details
PLN-74809 PLN-74809 Pliant Therapeutics Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis Details
[18F]FP-R01-MG [18F]FP-R01-MG; [18F]FP-R01-MG-F2 Phase 1 Clinical Pliant Therapeutics, Stanford University, Chinese Academy Of Medical Science & Peking Union Medical College Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Cholangitis, Sclerosing; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop